Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice GuidelineSaro H. Armenian, Daniel J. Lenihan, Christina Lacchetti et al.|Journal of Clinical Oncology|2017Cited by 1.3k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Daniel J. Lenihan, Teresa López‐Fernández et al.|European Journal of Heart Failure|2020Cited by 767
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Peter Valent, Daniel J. Lenihan et al.|European Heart Journal|2021Cited by 589
Genetic Variants Associated With Cancer Therapy–Induced CardiomyopathyPablo García‐Pavía, Bonnie Ky, Ida G. Lunde et al.|Circulation|2019Cited by 346
Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyRadek Pudil, Alexander R Lyon, Christian Mueller et al.|European Journal of Heart Failure|2020Cited by 344